WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Change in Management
Pursuant to Regulation 30 of SEBI(Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform you that Mr Prasanna Bharatan has resigned as Internal Auditor of the Company with effect from closing of business hours on Friday, 5th July 2024. WOCKHARDT LTD. - 532300 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI Listing Regulations, our RTA has intimated about receipt of the requests for issuance of duplicate share certificate(s) in lieu of original share certificate(s) reported lost/misplaced. Wockhardt enters last mile to bring two of its promising antibiotics to India
Out-licencing talks for overseas markets, after global approvals, says Chairman WOCKHARDT LTD. - 532300 - Disclosure Of Voting Results Of 25Th Annual General Meeting ('AGM') Pursuant To Regulation 44(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 44(3) of SEBI(LODR) Regulations, 2015, we enclose herewith the combined voting Results of remote e-voting and e-voting during the 25th Annual General Meeting of the Company held on 28th June, 2024 along with the scrutinizer''s report thereon. Wockhardt stock soars over 19% after its investigational antibiotic Zaynich successfully treats cancer patient in US
This marked the first instance in US, where Zaynich had been used to combat a complex infection caused by extreme-drug-resistant pseudomonas Wockhardt's novel antibiotic Zaynich to be launched in India by end of FY25
Global launch in FY26 after multinational clinical trial ends
Wockhardt Launches New Antibiotic With $25-Billion Market Potential
The company has invested over $500 million on its research efforts till now. WOCKHARDT LTD. - 532300 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Please find enclosed herewith the Scrutinizer''s Report on the voting results of remote e-voting and e-voting during the 25th AGM of the Company held today i.e. 28th June, 2024 WOCKHARDT LTD. - 532300 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Wockhardt Limited has informed regarding the press release dated June 28, 2024 titled "Globally renowned US body Clinical & Laboratory Standard Institute (CLSI) awards high susceptibility breakpoints to Zaynich (Zidebactam/Cefepime-WCK 5222)".